Enoxaparin Sodium Injection IP

Trade Name: VacEnoxa
Available Strength : 40 mg
Available Combination : Enoxaparin Sodium Injection IP is a low-molecular-weight heparin anticoagulant used to prevent and treat blood clots by inhibiting clot formation and improving blood flow.
Packing : 0.4 ml PFS
Pack Insert/Leaflet : YES
Therapeutic use : Enoxaparin Sodium Injection IP is a low-molecular-weight heparin used to prevent and treat thromboembolic disorders such as deep vein thrombosis (DVT) and pulmonary embolism. It is widely used in postoperative and bedridden patients, and in acute coronary syndromes like unstable angina and myocardial infarction, where it helps prevent clot formation and improves blood circulation.
Capacity : 100000

Additional Information

The most common markets for this product include the following countries. Please inquire with us if your country or region is not listed:

Asia: Afghanistan, Israel, Jordan, Pakistan, Russia, Saudi Arabia, Singapore, Syria, Philippines, Turkey, Turkmenistan, Uzbekistan, Yemen, Vietnam, Indonesia, Malaysia, Iran, Tajikistan, etc.

Africa: South Africa, Uganda, Nigeria, Ghana, Kenya, Mauritius, Botswana, Egypt, Ethiopia, Libya, Sudan, Congo, Gambia, Ivory Coast , etc.

Africa: South Africa, Uganda, Nigeria, Ghana, Kenya, Mauritius, Botswana, Egypt, Ethiopia, Libya, Sudan, Congo, Gambia, Ivory Coast , etc.

Europe: Austria , Azerbaijan, Belarus, Belgium, Cyprus, Czech Republic, Denmark, France, Georgia, Germany, Hungary, Ireland, Iceland, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Ukraine, United Kingdom (UK) , Latvia, etc.

OCEANIA: Australia, New Zealand, Fiji, etc.